Gilead Sciences, Inc business logo
Medicine Questions
Report an Adverse Event
Investors
Contact
Global Operations
North America
  • Canada
  • Mexico
  • USA
South America
  • Argentina
  • Brazil
Asia
  • China
  • Hong Kong
  • India
  • Japan
  • Korea
  • Singapore
  • Taiwan
Middle East
  • Saudi Arabia
  • Israel
  • Turkey
  • United Arab Emirates
Africa
  • South Africa
Australia
  • Australia New Zealand
Europe
  • Austria
  • Belgium Luxembourg
  • Czech Republic & Slovakia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Poland & The Baltics
  • Portugal
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
Gilead Logo
  • Our Purpose
    Mission and Core Values Partnerships and Community Inclusion and Diversity Corporate Giving Gilead Foundation Sustainability Advancing Global Health Medication Access
  • About
    Leadership U.S. Locations How We Operate Ethics and Code of Conduct
  • Science & Medicine
    Medicines Pipeline Research Clinical Trials
  • News and Press
    Events Stories Newsroom Company Statements Annual Reports
  • Careers
    Careers at Gilead Our Culture Meet Our Employees Inclusion and Diversity in Hiring Compensation, Benefits and Wellbeing Our Global Footprint Early Career Opportunities Hiring Events Talent Community Sign-up
  • Utility
    Privacy Statements Terms Of Use Social Media Guidelines EU Data Disclosure Sitemap
BACK TO MAIN MENU Partnerships and Community COMPASS Initiative HepConnect HIV Age Positively Lift RADIAN TRANScend
BACK TO MAIN MENU Corporate Giving What We Fund Funding Requests Zeroing In: Ending the HIV Epidemic
BACK TO MAIN MENU Gilead Foundation Creating Possible Fund
BACK TO MAIN MENU Sustainability Our Business Is Sustainable Performance Reporting U.N. Global Compact U.N. Sustainable Development Goals
BACK TO MAIN MENU Advancing Global Health COVID-19 HCV Elimination
BACK TO MAIN MENU Medication Access U.S. Patient Access Disaster Product Replacement Global Access Authorized Distributors
BACK TO MAIN MENU How We Operate ESG Goals Governance Transparency
BACK TO MAIN MENU Ethics and Code of Conduct Policies Anti-Bribery and Anti-Corruption Policy Animal Use and Welfare Policy Disclosures Anti-Counterfeiting Consumer Product Safety Supplier Information Political Engagement
BACK TO MAIN MENU Research Research Scholars Program Compassionate Use Investigator-Sponsored Research
BACK TO MAIN MENU Newsroom Press Releases Media Inquiries
BACK TO MAIN MENU Company Statements Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Gilead to Expand Footprint in Oceanside Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
BACK TO MAIN MENU Annual Reports Year in Review 2021
BACK TO MAIN MENU Privacy Statements Cookie Statement
BACK TO MAIN MENU
North America
  • Canada
  • Mexico
  • USA
South America
  • Argentina
  • Brazil
Asia
  • China
  • Hong Kong
  • India
  • Japan
  • Korea
  • Singapore
  • Taiwan
Middle East
  • Saudi Arabia
  • Israel
  • Turkey
  • United Arab Emirates
Africa
  • South Africa
Australia
  • Australia New Zealand
Europe
  • Austria
  • Belgium Luxembourg
  • Czech Republic & Slovakia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Iceland
  • Ireland
  • Italy
  • Netherlands
  • Norway
  • Poland & The Baltics
  • Portugal
  • Russia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom
BACK TO MAIN MENU

Contact

  • Request Medicines Information
  • Report an Adverse Event
  • Partnership Request
  • Medicine Questions
  • Report an Adverse Event
  • Investors
  • Contact
  • Global Operations
Toggle Inner Dropdown
BACK TO MAIN MENU Google.com
  • Events
  • Stories
  • Newsroom
    • Press Releases
    • Media Inquiries
  • Company Statements
    • Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission
    • Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products
    • Gilead to Expand Footprint in Oceanside
    • Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities
    • Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare
    • Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain
    • Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
    • Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
    • Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates
    • Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
    • Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir
    • Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union
    • Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer
    • Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees
    • Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States
    • Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis
    • Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)
    • Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer
    • Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19
    • Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
    • Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
    • Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services
    • Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD
    • Gilead Sciences Statement on Recent Events in Washington, D.C.
    • Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®
    • Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines
  • Annual Reports
    • Year in Review 2021

Newsroom

Sara Tolaney on Gilead’s Research Scholars Program and the Importance of Diversity in Medicine

This unique program provides support to early-career investigators doing highly innovative basic and clinical research.

Stories@Gilead - May 25, 2022

Sara Tolaney

Recent Story Posts

Community

Sara Tolaney on Gilead’s Research Scholars Program and the Importance of Diversity in Medicine

Stories@Gilead - May 25, 2022

Teenagers walking down the street
Community

Portugal’s Positive Approach to Teaching Teens about the Birds, Bees and STIs

Stories@Gilead - May 18, 2022

Culture

4 Questions with Betty Chiang: Addressing Health Disparities in the Asian Community

Stories@Gilead - May 11, 2022

Recent Press Releases

  • May 19, 2022

    Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
  • May 17, 2022

    Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

Explore More

View Upcoming Events

Company Statements

2021 Year in Review

Twitter
 

For more information, contact us.

Phone:
1-800-GILEAD-5 (1-800-445-3235) 1-800-GILEAD-5 (1-800-445-3235)

Email:
public_affairs@gilead.com

Gilead Sciences, Inc business logo

© 1996-2022 Gilead Sciences, Inc. All rights reserved.

AREAS OF INTEREST

  • Partnerships and Community
  • Pipeline
  • Medicines
  • Job Search

INFORMATION

  • Contact Us
  • Report an Adverse Event
  • Press Room
  • Investor Calls
  • Sitemap

LEGAL

  • Privacy Statement
  • Terms of Use
  • EU Data Disclosure
  • Social Media Guidelines
  • Modern Slavery Act Statement

FOLLOW US

  • twitter
  • linkedin
  • Instagram
  • facebook
  • youtube

Headline

Intersititial body copy

Ok Cancel